RHEUMATOLOGISTS EXPRESS SIGNIFICANT INTEREST IN BENLYSTA, THE FIRST NOVEL DRUG FOR THE TREATMENT OF LUPUS IN DECADES

ACORDA’S AMPYRA IS SEEN AS A WELCOMED ADDITION TO EXISTING DISEASE-MODIFYING AGENTS FOR THE IMPROVEMENT OF WALKING SPEED IN MULTIPLE SCLEROSIS PATIENTS, ACCORDING TO U.S NEUROLOGISTS, EVEN AS PRODUCT ACCESS PROVES FRUSTRATING

USE OF CENTOCOR-ORTHO BIOTECH’S STELARA (USTEKINUMAB) IS ON AN UPSWING AS FAMILIARITY INCREASES AND EXPERIENCE WITH THE PRODUCT PRODUCES EXCELLENT OUTCOMES, ACCORDING TO U.S. DERMATOLOGISTS